2
Clinical Trials associated with Tenecteplase biosimilar(Generium Pharmaceuticals)Multicenter Randomized Single Blind Study of the Clinical Efficacy and Safety of GNR-060 (JSC "GENERIUM", Russia) Compared to Metalyse (Boehringer Ingelheim Pharma GmbH & Co.KG, Germany) in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST Elevation Myocardial Infarction (STEMI).
A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction
To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)
100 Clinical Results associated with Tenecteplase biosimilar(Generium Pharmaceuticals)
100 Translational Medicine associated with Tenecteplase biosimilar(Generium Pharmaceuticals)
100 Patents (Medical) associated with Tenecteplase biosimilar(Generium Pharmaceuticals)
100 Deals associated with Tenecteplase biosimilar(Generium Pharmaceuticals)